TransCode Therapeutics heads into the back half of May carrying a 26% one-month price loss, a freshly filed shelf registration, and short interest that has just ticked back up after a multi-week retreat.
The most significant catalyst context is the April 30 S-1 filing. TransCode registered up to 15.96 million shares for resale by selling stockholders — a large number relative to a company with a market cap of roughly $6.3 million. That overhang has been the clearest weight on the stock, which fell from above $10 in late February to $6.60 by May 15. The Q1 results released this week showed EPS of -$21.28 per share, a meaningful improvement from -$70.16 a year ago, but the improvement has done little to reverse the slide.
Short interest has been rebuilding after a long unwind. At 4.4% of the free float as of May 14, it has risen 13% over the past week — recovering from multi-week lows reached in mid-April, when short interest had pulled back from a peak near 5.8%. The cost to borrow is running at 22.2%, elevated but well below the 38–39% levels seen in early April. Borrow availability is roughly 87% of short interest, meaning the lending pool is not particularly tight — there is no squeeze pressure in the current setup. The ORTEX short score has climbed to 67.2 from 60.6 ten days ago, marking its highest point in the recent window and reflecting the combination of rising shorts, continued borrow cost, and the price decline.
There is no current analyst coverage to speak of, and valuation multiples are not meaningful given the pre-revenue stage and negative enterprise value on the books. The EPS surprise factor score ranks in the 88th percentile — TransCode has been beating estimates consistently on a relative basis — but the absolute loss figures remain deep negative, and the improvement in quarterly EPS is still a function of reduced operating activity rather than revenue generation. The company's sector score sits at the 50th percentile, unremarkable for a micro-cap biotech at this stage.
Institutional ownership is thin. DEFJ, LLC holds 8.8% of shares and was last reported as of early May with no change. Sabby Management held 4.4% as of year-end 2025, having entered the position from zero. The insider data is stale — the most recent trades on record date to September 2023, when the CEO and CFO were buying at $0.51 per share, a price level the stock has long since left behind in both directions.
The past four earnings-adjacent events have produced mixed moves: a 5.2% one-day decline in April 2026, an 8.4% gain in mid-April, a 2.2% decline in another April event, and a 5.7% gain in November 2025. The pattern is choppy rather than directional, with no consistent post-event drift. With no next earnings date confirmed, the immediate calendar is quiet.
What to watch: whether the S-1 resale overhang translates into actual selling by the named stockholders, how the short score moves as the week-on-week SI rebuild either continues or stalls, and whether the Q1 EPS improvement draws any institutional attention to the name at current price levels.
See the live data behind this article on ORTEX.
Open RNAZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
